MapLight Therapeutics, Inc. (MPLT)
6.93
+0.71
(+11.41%)
USD |
NASDAQ |
Nov 06, 16:00
7.59
+0.66
(+9.52%)
After-Hours: 20:00
MapLight Therapeutics Research and Development Expense (Annual) : 138.35M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 138.35M |
| December 31, 2024 | 67.82M |
| Date | Value |
|---|---|
| December 31, 2023 | 49.12M |
| December 31, 2022 | 26.57M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Cullinan Therapeutics, Inc. | 187.40M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |
| Sarepta Therapeutics, Inc. | 1.493B |